Hepatitis C virus RNA and anti-N14 antibody levels during interferon alpha therapy for chronic hepatitis C. 1994

M Oketani, and K Tanaka, and Y Sho, and E Maeda, and H Miyazaki, and T Arima
Second Department of Internal Medicine, Faculty of Medicine, Kagoshima University.

To investigate the markers useful for evaluating the long-term efficacy of interferon (IFN) therapy, the quantity of hepatitis C virus (HCV) RNA and two anti-HCV antibody titers (anti-N14 and anti-C-100-3 antibody) in 21 chronic hepatitis C patients were determined. In all complete responders, a sustained clearance of the virus and reductions in the anti-HCV antibody titers were observed during and after therapy. In most of the temporary responders, reductions in the HCV RNA levels and in both anti-HCV antibody titers were observed temporarily during the therapy, and relapse followed. In nonresponders, although the HCV RNA levels and anti-N14 antibody titer tended to remain unchanged or increased during and after therapy, the anti-C-100-3 antibody titers showed no tendency. These results demonstrate that the monitoring of the HCV RNA level and anti-N14 antibody titer is clinically useful for following the patient's response to IFN therapy for chronic hepatitis C.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D005260 Female Females
D006508 Hepatitis Antibodies Immunoglobulins raised by any form of viral hepatitis; some of these antibodies are used to diagnose the specific kind of hepatitis. Antibodies, Hepatitis
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic

Related Publications

M Oketani, and K Tanaka, and Y Sho, and E Maeda, and H Miyazaki, and T Arima
April 1996, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology,
M Oketani, and K Tanaka, and Y Sho, and E Maeda, and H Miyazaki, and T Arima
October 1992, Gastroenterology,
M Oketani, and K Tanaka, and Y Sho, and E Maeda, and H Miyazaki, and T Arima
August 2003, The British journal of dermatology,
M Oketani, and K Tanaka, and Y Sho, and E Maeda, and H Miyazaki, and T Arima
November 1991, Annals of internal medicine,
M Oketani, and K Tanaka, and Y Sho, and E Maeda, and H Miyazaki, and T Arima
July 1994, Journal of hepatology,
M Oketani, and K Tanaka, and Y Sho, and E Maeda, and H Miyazaki, and T Arima
March 2000, Gastroenterologie clinique et biologique,
M Oketani, and K Tanaka, and Y Sho, and E Maeda, and H Miyazaki, and T Arima
March 1993, Antimicrobial agents and chemotherapy,
M Oketani, and K Tanaka, and Y Sho, and E Maeda, and H Miyazaki, and T Arima
May 1993, Gastroenterologia Japonica,
M Oketani, and K Tanaka, and Y Sho, and E Maeda, and H Miyazaki, and T Arima
July 1994, Nihon rinsho. Japanese journal of clinical medicine,
M Oketani, and K Tanaka, and Y Sho, and E Maeda, and H Miyazaki, and T Arima
December 1998, The American journal of gastroenterology,
Copied contents to your clipboard!